Gemtuzumab Ozogamicin OverviewGemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010. It was withdrawn from market in June 2010 when a clinical trial showed the drug increased patient death and added no benefit over conventional cancer therapies. It was re-introduced into the US market in 2017. Contents 1 Mechanism and side effects 2 History 3 See also 4 References Me...
Read more Gemtuzumab Ozogamicin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Gemtuzumab_ozogamicin
Recent Gemtuzumab Ozogamicin Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 5mg, 5mg/vial
- Vial: 4.5mg